IMPAACT 2016 is a multi-site, two-arm, individually randomized, controlled study to evaluate whether an Indigenous Leader Outreach Model (ILOM) of trauma-informed cognitive behavioral therapy (TI-CBT) delivered by Indigenous Youth Leaders (IYL) is associated with improved mental health outcomes and ART adherence among youth living with HIV in resource-limited settings. The intervention is adapted to the local context through advance conduct of focus groups and pilot testing.
IMPAACT 2016 is a multi-site, two-arm, individually randomized, controlled study to evaluate whether an Indigenous Leader Outreach Model (ILOM) of trauma-informed cognitive behavioral therapy (TI-CBT) delivered by Indigenous Youth Leaders (IYL) is associated with improved mental health outcomes and ART adherence among youth living with HIV in resource-limited settings. To adapt the intervention for the local context, the trial will be preceded by an adaption of the TI-CBT intervention at each site using the "ADAPT-ITT" model, which includes focus groups and pilot tests. In the randomized study, youth will be individually randomized to either the TI-CBT Intervention Arm or the Discussion Control Arm. Participants will meet as a group within their randomized arm and receive multiple group sessions within an eight-week period. Each group will include an average of eight youth for an approximate total of 192-256 youth in the Randomized Trial (96-128 youth per arm). TI-CBT and Discussion Control groups in each arm will be mixed-gender unless it is determined necessary to have single-gender groups during the focus group. Caregivers (as available and with youth permission) will be assigned to the same study arm as their youth. Caregivers will meet as a group for two caregiver-specific sessions on two separate weeks and separate from their youth group sessions. Youth and caregivers will complete a follow-up visit immediately after their last group session and two additional follow-up visits at six and 12 months. Youth and caregivers will also receive one two-hour booster group session consistent with their assigned study arm immediately after the six-month evaluations. The booster sessions are intended to enhance treatment effects and increase sustainability. Once all participants have completed their six-month evaluations, data from these evaluations will be analyzed to determine the short-term effects of the intervention. Additional analyses to assess the longer-term effects of the intervention, including the effects of the booster group session, will be performed after the completion of follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
256
TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and "mastery of trauma", which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial.
Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
Gaborone Prevention/Treatment Trials CRS 12701
Gaborone, Botswana
Molepolole Prevention/Treatment Trials CRS 12702
Molepolole, Botswana
College of Medicine CRS 30301
Blantyre, Malawi
University of North Carolina Lilongwe CRS 12001
Lilongwe, Malawi
Soweto IMPAACT CRS 8052
Soweto, South Africa
St. Mary's CRS 30303
Chitungwiza, Zimbabwe
Harare Family Care CRS 31890
Harare, Zimbabwe
Seke North CRS 30306
Harare, Zimbabwe
Patient Health Questionnaire-9
(PHQ-9, measure of depression: range 0-27, higher=worse)
Time frame: at 6-months
General Anxiety Disorder-7
(GAD-7, measure of anxiety: range 0-21, higher=worse)
Time frame: at 6-months
UCLA Post-Traumatic Stress Disorder-Reaction Index
(UCLA PTSD-RI, measure of TPSD: range 0-51, higher=worse)
Time frame: at 6-months
Composite mental health measure
(measure of combined mental health issues: PHQ-9, GAD-7, and UCLA PTSD-RI scores will be standardized to have mean=0, standard deviation=1, and then summed; higher=worse)
Time frame: at 6-months
Patient Health Questionnaire-9
(PHQ-9, measure of depression: range 0-27, higher=worse)
Time frame: after initial treatment completion (an average of 6 weeks)
General Anxiety Disorder-7
(PHQ-9, measure of depression: range 0-27, higher=worse)
Time frame: after initial treatment completion (an average of 6 weeks)
UCLA Post-Traumatic Stress Disorder-Reaction Index
(UCLA PTSD-RI, measure of TPSD: range 0-51, higher=worse)
Time frame: after initial treatment completion (an average of 6 weeks)
Composite mental health measure
(measure of combined mental health issues: PHQ-9, GAD-7, and UCLA PTSD-RI scores will be standardized to have mean=0, standard deviation=1, and then summed; higher=worse)
Time frame: after initial treatment completion (an average of 6 weeks)
ART Adherence
Self-report - Wilson 3-item scale (range 0-100, higher=better)
Time frame: after initial treatment completion (an average of 6 weeks), and at 6-months
Viral Load
HIV-1 RNA
Time frame: after initial treatment completion (an average of 6 weeks), and at 6-months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.